

Supplementary materials

Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies

Eduardo Pérez del Río,^{1,2} Macarena Román Alonso,^{3,4} Irene Rius,^{3,4} Fabião Santos,^{1,2} Miquel Castellote-Borrell,^{1,5} Jaume Veciana,^{1,2} Imma Ratera,^{a,b} Joaquín Arribas,^{3,4,6,7,} Judith Guasch^{1,2,5,*}*

¹ Institute of Materials Science of Barcelona (ICMAB-CSIC), Bellaterra, Spain

² Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain

³ Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

⁴ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain

⁵ Dynamic Biomaterials for Cancer Immunotherapy, Max Planck Partner Group (ICMAB-CSIC), Bellaterra, Spain

⁶ Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

⁷ Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain

* Correspondence: jguasch@icmab.es; jarribas@vhio.net

1. Differentiation results of PBMCs




Figure S1. Differentiation analysis of PBMCs 5 days after seeding showing the percentages of CD45RO-/CD62L+, CD45RO+/CD62L+, and CD45RO+/CD62L- ($N_{\text{donors}} = 6$). Statistical significance was determined by the Mann-Whitney U test in all cases (* $p < 0.05$, ** $p < 0.01$).

2. Differentiation results of CAR+CD4+ T cells




Figure S2. Differentiation analysis of the resulting CAR+CD4+ T cells produced from PBMCs at day 10 ($N_{\text{donors}} = 3$).